These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22305890)

  • 1. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
    Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
    Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.
    Chen J; Hou J; Zhang J; An Y; Zhang X; Yue L; Liu J; Li X
    Eur J Pharmacol; 2012 May; 682(1-3):161-70. PubMed ID: 22510296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
    Katiyar SK; Meeran SM; Katiyar N; Akhtar S
    Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
    Pan Y; Li X; Duan J; Yuan L; Fan S; Fan J; Xiaokaiti Y; Yang H; Wang Y; Li X
    Mol Pharmacol; 2015; 87(3):378-90. PubMed ID: 25488183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin.
    Kang JH; Kang HS; Kim IK; Lee HY; Ha JH; Yeo CD; Kang HH; Moon HS; Lee SH
    Exp Biol Med (Maywood); 2015 Nov; 240(11):1416-25. PubMed ID: 25716014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
    Kong M; Fan J; Dong A; Cheng H; Xu R
    Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
    Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
    Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
    Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
    PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
    Zheng X; Cui XX; Avila GE; Huang MT; Liu Y; Patel J; Kong AN; Paulino R; Shih WJ; Lin Y; Rabson AB; Reddy BS; Conney AH
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5480-7. PubMed ID: 17875778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
    Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X
    Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
    Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.